$1.020
+0.029 (+2.87%)Zum Schluss
LSTA-News
LSTA-Events
Lisata Therapeutics Granted New Patent for Treating Pancreatic Cancer
Lisata Therapeutics announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,751,991, a new method of use patent for certepetide in treating pancreatic cancer and other solid tumors, expiring May 2041. The patent covers giving the company's cyclic peptide together with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors, including metastatic, refractory and drug-resistant cancers.
Lisata Therapeutics Sues Kuva Labs for Breach and Cuts 72% of Workforce
Lisata Therapeutics provided an update following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp. The company said, "Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva's breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 seeking, among other things, damages for the benefit of its stockholders and the $2,000,000 termination fee Lisata is owed under the Merger Agreement. Lisata's Board of Directors continues to evaluate strategic alternatives to enhance stockholder value, which will include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets, liquidation and dissolution, among other strategic transactions. The Company has not set a timetable for completion of this strategic review and does not intend to comment further on the status of this process unless or until its Board of Directors has approved a definitive course of action, or it is determined that another disclosure is warranted. In order to reduce operating expenses and preserve cash to pursue strategic alternatives, Lisata has implemented a reduction in force, eliminating approximately 72% of its full-time employees, including its Executive Vice President of R&D and Chief Medical Officer position. Certain members of the separated staff may be engaged as external consultants for a period of time, as necessary."
Lisata Therapeutics Acquired by Kuva Labs at $5.00 per Share
Lisata Therapeutics announced that it has entered into a definitive agreement to be acquired by Kuva Labs, a privately-held company. Under the terms of the merger agreement, Kuva will commence a tender offer to acquire all the issued and outstanding shares of common stock of the company for $5.00 per share in cash payable at closing plus one contingent value right per share. The CVR entitles the holders of record to receive an additional cash payment of $1.00 per share if a New Drug Application or similar registration is filed or formally accepted for review by the FDA or any governmental authority in any jurisdiction with respect to any pharmaceutical product that contains or incorporates the product candidate referred to as of the date of the merger agreement as certepetide for any indication or patient population prior to the earlier of (a) 11:59 p.m. New York City Time on the seventh (7th) anniversary of the closing date, and (b) termination of the CVR agreement. Should the relevant milestone not be met, then no additional consideration will be payable to the holders of the CVRs in relation to such milestone. The Transaction is subject to customary offer conditions contained in the merger agreement that will be filed with the SEC, including the tender of a majority of the outstanding shares of the company's capital stock. The merger agreement does not include a financing condition. The Transaction is expected to close in the second quarter of 2026, subject to satisfaction of the offer conditions. If the tender offer closes, then Kuva would acquire the untendered shares and convertible securities of the company through a second-step merger for the same consideration. Following completion of the Transaction, Lisata will become part of Kuva, a privately-held company, and its common stock will be delisted from the Nasdaq Capital Market. Lisata will also apply to deregister its common stock and cease to be a reporting company under the United States Securities Exchange Act of 1934, as amended
Lisata Terminates Exclusive License Agreement with Qilu Pharmaceutical
Lisata Therapeutics has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical. The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product candidate, in the Greater China region including Mainland China, Hong Kong, Macau, and Taiwan. This action results in all licenses and other rights granted to Qilu reverting to Lisata. Notwithstanding, Qilu maintains its obligations, regulatorily or otherwise, to complete and wind down their ongoing Phase 2 clinical study evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma. Lisata has agreed to negotiate with Qilu the potential licensing of relevant study data from this trial, as appropriate.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.